KDM1A and breast carcinoma: Despite early literature suggesting LSD1 inhibitors would be broadly active in numerous cancers including colon, prostate, and breast cancer [12, 52, 53], the generation of more selective LSD1 inhibitors has clarified the extent of LSD1 inhibitor activity primarily in AML and SCLC [5, 54].